Major investment for respiratory diseases completed
105 million euros invested into expansion of production facilities in Ingelheim and Dortmund
Search
Shared science for the best cat diabetes management
Diabetes mellitus is a common endocrine disease with increasing prevalence in dogs and cats. Learn how science's made management easier.
Striving to revolutionize mental health research
World Mental Health Day: Through a precision psychiatry approach and rich pipeline, we are committed to transforming the mental health landscape.
Partnering-with-google-in-quantum-computing
New cooperation with Google explores the potentials of quantum computing for pharma R&D.
Clinical-phase2-trials-NASH-and-obesity
Boehringer Ingelheim and Zealand Pharma announced Phase 2 trials of the GLP-1/glucagon dual agonist BI 456906 for adults living with obesity or NASH.
Boehringer Ingelheim Second Transforming Science Day
World-renowned top scientists and companies in R&D take the stage at Boehringer Ingelheim’s second Transforming Science Day
Innovation in medicinal chemistry
Darryl McConnell, Research Site Head, Austria and Jürgen Mack, Medicinal Chemistry, explain how we are working to unlock unsolved diseases
Nerandomilast primary endpoint phase-3 FIBRONEER-IPF met
Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER™-IPF study
EU approved Jardiance for type 2 diabetes in children
Jardiance® (empagliflozin) receives approval in the EU for the treatment of type 2 diabetes in children aged 10 years and above
new_analysis_nintedanib_SSc_ILD
Interim analysis results support long term treatment with nintedanib in SSc-ILD patients
Nerandomilast (BI 1015550)
Nerandomilast (BI 1015550): PDE4B inhibitor
Ingelheim
The company headquarters of Boehringer Ingelheim are located in Ingelheim, Germany.
Supply Chain Scholarship for Cowtribe
A supply chain course we sponsored boosted the career of Latifa Saaka
Mastitis dairy cows prevent antibiotic resistance
The Clinical and Laboratory Standards Institute (CLSI) approved revised interpretive criteria for the susceptibility testing of a mastitis product.
AUROBAC's Strategy & Pipeline Against Severe Infections & Resistance
AUROBAC THERAPEUTICS presents strategy and growing pipeline to tackle severe infections and antimicrobial resistance
Employees empower small dairy producers
Boehringer Ingelheim social intrapreneurship helps farmers improve animal welfare and the well-being of rural communities in Southern India.
Purpose: Finding the long-missed meaning
Cancer survivor Missy Pappion is happy at Boehringer Ingelheim after climbing the corporate ladder
Stroke Risk Factors Symptoms
Suffering a stroke is one of the most devastating medical emergencies that can happen to a person. There is a simple test that can help everyone identify the most common symptoms of a stroke.
global-top-employer
For the first time, Boehringer Ingelheim receives the award as a Global Top Employer as well as individual awards in 27 countries.
Award: Boehringer Ingelheim is Global Top Employer 2022
Global Top Employer 2022
Animal Welfare through environmental sustainability
Producing honey and contributing to environmental sustainability during your work hours.
Larry’s Story: Advocating for people with lung cancer
In 2013, Larry was diagnosed with non-small cell lung cancer. Learn how his diagnosis led him on a journey of patient advocacy for others with cancer.
GPP Forum Article - Frida Dunger Johnsson, Executive Director, IFPA
Frida Dunger Johnsson, Executive Director of IFPA and panelist at the generalized pustular psoriasis (GPP) Forum, reflects on a momentous day
Boehringer Ingelheim: Discover the app set to transform animal care in rural India
Learn about the app set to transform animal care in rural India. Women will be empowered and goat welfare will be promoted. From idea to app!
Boehringer Ingelheim half-year results 2023
First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas